ReviewAdvances in experimental medicine and biology2026
New Sialic Acid-Binding Site of SIGLEC-7.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prediction of Novel Disease-Related Regions in SIGLEC-7 byInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sialic acid is a code for "recognize-me-as-self" (a "see-me-as-self" signal) on cells or molecules for immune cells that survey non-self-items. One of the mechanisms in discrimination of self- and non-self-items is the presence of sialic acid-binding immunoglobulin-like lectins (SIGLECs) on the immune cell surface. SIGLECs have a dual role with respect to host cells in the innate immune system. Under normal conditions, the ability of SIGLECs to discriminate non-self from self is important in inhibiting attacks on the self-cells. However, cancer cells and sometimes bacterial cells can misuse this system, using more sialic acid to cheat immune cells, as if they are self-cells, resulting in escape from the host immune system. SIGLEC-7 is an important inhibitory receptor predominantly expressed in natural killer cells. The ligand specificity of SIGLEC-7 is diverse and complex, and its surveillance mechanisms are unclear. In this chapter, we focus on ligand specificity from two perspectives. One is the clustering effect of the ligand on SIGLEC-7, and the other is a new sialic acid-binding site in addition to that previously discovered in SIGLEC-7. These perspectives inform the decoding of true biological contexts within the SIGLEC-sialic acid axis.
Indexed as
Identifiers
41917391What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.